Enzo Biochem (NYSE:ENZ – Get Rating) and Akumin (NASDAQ:AKU – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, institutional ownership, valuation, earnings and analyst recommendations.
Volatility and Risk
Enzo Biochem has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Akumin has a beta of -0.49, meaning that its stock price is 149% less volatile than the S&P 500.
Institutional & Insider Ownership
50.6% of Enzo Biochem shares are held by institutional investors. Comparatively, 25.8% of Akumin shares are held by institutional investors. 15.5% of Enzo Biochem shares are held by insiders. Comparatively, 18.2% of Akumin shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enzo Biochem | 0 | 0 | 0 | 0 | N/A |
| Akumin | 1 | 0 | 0 | 0 | 1.00 |
Akumin has a consensus target price of $0.50, indicating a potential downside of 10.71%. Given Akumin’s higher probable upside, analysts plainly believe Akumin is more favorable than Enzo Biochem.
Earnings and Valuation
This table compares Enzo Biochem and Akumin’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enzo Biochem | $107.07 million | 1.14 | -$18.26 million | ($0.72) | -3.42 |
| Akumin | $749.63 million | 0.07 | -$156.76 million | ($1.75) | -0.32 |
Enzo Biochem has higher earnings, but lower revenue than Akumin. Enzo Biochem is trading at a lower price-to-earnings ratio than Akumin, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Enzo Biochem and Akumin’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enzo Biochem | -43.44% | -67.73% | -36.44% |
| Akumin | -20.91% | -53.08% | -5.41% |
Summary
Akumin beats Enzo Biochem on 7 of the 12 factors compared between the two stocks.
About Enzo Biochem
Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.
About Akumin
Akumin, Inc. engages in the provision of fixed-site outpatient diagnostic imaging services and solutions. It operates under the Radiology and Oncology segments. The Oncology segment includes delivering ionizing radiation to treat malignant and benign disease processes under the direction of a radiation oncologist. The company was founded on August 12, 2015 and is headquartered in Plantation, FL.
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.
